CD20/CD22
Showing 1 - 25 of >10,000
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Acute Lymphocytic Leukemia Trial in Beijing, Tianjin (LCAR-AIO Cells)
Recruiting
- Acute Lymphocytic Leukemia
- LCAR-AIO Cells
-
Beijing, Beijing, China
- +1 more
May 31, 2022
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Beijing, Tianjin (LCAR-AIO cells product)
Recruiting
- B-cell Lymphoma Recurrent
- B-cell Lymphoma Refractory
- LCAR-AIO cells product
-
Beijing, Beijing, China
- +1 more
Apr 1, 2022
Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)
Recruiting
- Therapy Related Leukemia
- Sequential Treatment With different CART
-
Guangdong, Guangdong, ChinaSouthern Medical University Zhujiang Hospital
Aug 9, 2021
19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)
Recruiting
- 19 and 22+ B Cell Hematologic Tumors
- 19 and 20+ B Cell Hematologic Tumors
- Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
-
Wuhan, Hubei, ChinaTongji Hospital
Jan 11, 2023
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg
Recruiting
- B-cell Non Hodgkin Lymphoma
- B-cell Chronic Lymphocytic Leukemia
- Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
- +3 more
-
Milwaukee, WisconsinMedical College of Wisconsin and Froedtert Hospital
Jul 1, 2022
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
Relapsed and Refractory, Lymphoid Hematological Malignancies Trial in Hangzhou (CD20/CD22 dual Targeted CAR T-cells)
Recruiting
- Relapsed and Refractory
- Lymphoid Hematological Malignancies
- CD20/CD22 dual Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 20, 2020
Leukemia, B-Cell Trial in Houston (Autologous TriCAR T-cells and lymphodepletion chemo)
Not yet recruiting
- Leukemia, B-Cell
- Autologous TriCAR T-cells and lymphodepletion chemotherapy
-
Houston, Texas
- +1 more
Nov 3, 2021
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5
Withdrawn
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +7 more
- Inotuzumab Ozogamicin
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 13, 2022
Non Hodgkin's Lymphoma, NHL, Aggressive NHL Trial in United States (Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab
Withdrawn
- Non Hodgkin's Lymphoma
- +3 more
- Veltuzumab and 90Y-Epratuzumab Tetraxetan
- +2 more
-
Newark, Delaware
- +6 more
Aug 12, 2021
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Acute Lymphoid Leukemia
- +4 more
- fludarabine
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)
Recruiting
- Hairy Cell Leukemia
- Hairy Cell Leukemia Variant
- CD22CART cell infusion
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous
Suspended
- B Cell Lymphoma
- +2 more
- Fludarabine
- +2 more
-
Stanford, CaliforniaStanford Medical Center
Sep 8, 2022
CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)
Recruiting
- Central Nervous System Lymphoma
- Human CD19-CD22 Targeted T Cells Injection
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Dec 13, 2022
Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)
Not yet recruiting
- Lymphoma, B-Cell
- CD19 and CD22 targeted CAR-T cells
-
Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
Dec 6, 2022
CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)
Recruiting
- CD20-positive Non-Hodgkin Lymphoma
- EX103 injection
-
Zhengzhou, Henan, China
- +3 more
Aug 28, 2023
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)
Active, not recruiting
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- CD19-CD22 CAR-T cells
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 2, 2022
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute
Recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Dasatinib
- +4 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 16, 2022
B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- +2 more
- Azacitidine Injection
- +2 more
- (no location specified)
Oct 15, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Suzhou (CD22/CD19 CAR T and auto-HSCT "sandwich" strategy)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jul 20, 2022
Lymphoma Trial in Houston (PCV20)
Not yet recruiting
- Lymphoma
- PCV20
-
Houston, TexasM D Anderson Cancer Center
Sep 20, 2023